What is HC Wainwright’s Forecast for Alumis FY2024 Earnings?

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at HC Wainwright raised their FY2024 earnings estimates for Alumis in a report released on Thursday, November 14th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($9.75) per share for the year, up from their prior estimate of ($11.42). HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Alumis’ current full-year earnings is ($7.98) per share. HC Wainwright also issued estimates for Alumis’ Q4 2024 earnings at ($1.39) EPS, Q1 2025 earnings at ($1.40) EPS, Q2 2025 earnings at ($1.41) EPS, Q3 2025 earnings at ($1.43) EPS, Q4 2025 earnings at ($1.45) EPS and FY2025 earnings at ($5.68) EPS.

Other equities research analysts have also issued reports about the company. Guggenheim assumed coverage on Alumis in a research note on Tuesday, July 23rd. They set a “buy” rating and a $32.00 price objective for the company. Baird R W upgraded Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. Leerink Partners initiated coverage on Alumis in a report on Tuesday, July 23rd. They issued an “outperform” rating and a $29.00 price objective on the stock. Leerink Partnrs raised shares of Alumis to a “strong-buy” rating in a report on Tuesday, July 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $26.83.

Alumis Price Performance

ALMS stock opened at $10.35 on Monday. Alumis has a 52 week low of $8.23 and a 52 week high of $13.53. The stock’s 50-day moving average is $11.16.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets purchased a new position in Alumis in the third quarter worth approximately $27,000. MetLife Investment Management LLC acquired a new position in shares of Alumis in the 3rd quarter valued at $89,000. Barclays PLC purchased a new position in shares of Alumis during the 3rd quarter worth $197,000. Maven Securities LTD acquired a new stake in shares of Alumis during the 2nd quarter worth about $332,000. Finally, State Street Corp acquired a new stake in shares of Alumis during the 3rd quarter worth about $866,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.